Thomas Zindrick Sells 4,509 Shares of Genelux (NASDAQ:GNLX) Stock

Genelux Corporation (NASDAQ:GNLX) CEO Thomas Zindrick sold 4,509 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $5.37, for a total transaction of $24,213.33. Following the sale, the chief executive officer owned 538,431 shares in the company, valued at $2,891,374.47. The trade was a 0.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Genelux Stock Down 2.4%

Shares of NASDAQ:GNLX traded down $0.11 during midday trading on Thursday, hitting $4.40. The stock had a trading volume of 77,387 shares, compared to its average volume of 191,698. The company’s 50-day moving average price is $5.74 and its 200-day moving average price is $4.17. Genelux Corporation has a fifty-two week low of $1.99 and a fifty-two week high of $8.53. The company has a market capitalization of $167.42 million, a P/E ratio of -5.00 and a beta of 0.06.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Research analysts expect that Genelux Corporation will post -0.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Lake Street Capital initiated coverage on Genelux in a research note on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Loop Capital set a $16.00 target price on Genelux in a research note on Tuesday, October 21st. Finally, Maxim Group set a $20.00 price target on shares of Genelux in a research note on Tuesday, October 21st. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Genelux has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Institutional Trading of Genelux

Several hedge funds and other institutional investors have recently made changes to their positions in GNLX. Goldman Sachs Group Inc. acquired a new position in shares of Genelux in the first quarter valued at approximately $239,000. Alyeska Investment Group L.P. bought a new stake in Genelux during the 1st quarter worth approximately $770,000. Woodward Diversified Capital LLC increased its position in Genelux by 21.7% in the 2nd quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company’s stock valued at $5,104,000 after acquiring an additional 317,173 shares during the period. OMERS ADMINISTRATION Corp bought a new position in shares of Genelux during the first quarter valued at $215,000. Finally, Global Retirement Partners LLC bought a new position in shares of Genelux during the second quarter valued at $656,000. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.